Lead Sponsor

AstraZeneca

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Patients with diagnosis of T2DM for \> 1 year prior to entry in the study willing and able to complete the questionnaire and on pharmacotherapy
•Patients who are currently treated with a single or combination of injectable/oral antidiabetic drugs with or without insulin therapy
•Treatment type must be unchanged in the previous 3 months. However, dose modifications are allowed
•Patients who agree to participate in the study and give their written informed consent

•Patients with type 1 diabetes
•Patients with diabetic ketoacidosis and/or hyperosmolar hyperglycaemic state
•Patients with secondary diabetes (including disease of the exocrine pancreas, endocrinopathies)
•Patients with concurrent treatment involving systemic glucocorticoids. However, inhaled, locally injected and topical use of glucocorticoids is allowed
•Patients suffering from severe cardiac, hepatic, renal diseases as judged by the investigator
•Any condition of the patient which may have an impact on objective and outcome of the trial example: patients currently undergoing major/ minor surgical

Related studies

NCT07340320 · Type II Diabetes Mellitus

NCT07350694 · Diabetes Type 2, Type II Diabetes Mellitus

NCT07119983 · Diabetic Foot Ulcer Associated With Type II Diabetes Mellitus

NCT06561126 · Type II Diabetes Mellitus, Intermediate Hyperglycemia (IHG)

NCT06030544 · Diabetic Patients, Type II Diabetes Mellitus

A Non-Interventional Study To Evaluate Diabetes Related Quality Of Life, Frequency And Impact Of Hypoglycemia In T2DM